Astellas will pay Vical $130 M for rights to its cytomegalovirus (CMV) vaccine to prevent the virus' reactivation in immunosuppressed transplant patients. A phase III trial of TransVax in hematopoietic stem cell transplant patients and a phase II study in solid organ transplant recipients will begin in 2012.
Astellas will develop and commercialize the vaccine in the US and for the rest of the world. It will also take on all development and commercialization costs. Vical will retain rights to co-promote in the US and provide manufacturing support. The deal extends Astellas offering in the transplant market -- a key focus area. See Fierce Biotech.
Posted by Bruce Lehr July 15th 2011.